Michael Dickinson is the Lead of the Aggressive Lymphoma stream at Peter Mac and Royal Melbourne, He is experienced as a principal investigator in phase I/II clinical trials of new anticancer drugs across a breadth of haematological malignancies. Michael’s clinical research includes industry and investigator-led trials in aggressive lymphomas, MDS/AML and phase 1-3 studies. Michael has been leading a research programme of T-cell engaging drugs in lymphoma. He has been working with the team at Peter Mac to develop and resource a CAR-T trials programme and is PI of several Novartis-sponsored trials. Michael has worked with the team at Peter Mac and Royal Melbourne to establish readiness for a standard of care CART service.